Developed thanks to more than 15 years of research by the San Raffaele Telethon Institute for Gene Therapy in Milan, Libmeldy is the first therapy approved for eligible patients with early-onset MLD
Di Micco’s project will investigate how blood stem cells respond to genetic manipulation, with the goal of making gene therapy safer and more effective
The prestigious recognition arrives for the first time in Italy and will support Di Micco’s research on blood stem cell therapies for rare genetic diseases
New research reveals immune predispositions in patients with life-threatening Covid-19
